Immunoregulation in the rat: cellular and molecular requirements for B cell responses to types 1, 2, and T-dependent antigens.
The requirements for primary in vitro plaque-forming cell (PFC) development in cultures of purified rat splenic B cells have been examined. Rat B cells were directly responsive to the type 1 antigen trinitrophenyl-Brucella abortus (TNP-BA), but both T cells and adherent accessory cells were required for B cell responses to the type 2 antigen TNP-Ficoll and the T cell-dependent (TD) antigen sheep erythrocytes (SRBC). However, the cellfree supernatants from concanavalin A-induced spleen cells of rat or mouse origin replaced the requirement for T cells and macrophages, and resulted in PFC development in response to TNP-Ficoll and SRBC and augmented PFC numbers in response to TNP-BA. Culture supernatants from induced murine T cell and macrophage cell lines were used to partially deduce the molecular requirements for the support of PFC development by rat B cells to these three antigens. Supernatants from the EL-4 (EL-4 sup) and B151 K12 (B15 sup) T cell lines augmented TNP-BA responses, suggesting that B cell growth factor II (BCGF-II) mediated this effect. An admixture of purified interleukin 2 (IL 2) and B15 sup supported PFC development to SRBC; indicating that IL 2, BCGF-II, and the T cell-replacing factor in B15 sup (B15-TRF) were sufficient to support this response. In addition, the IL 2 plus B15 sup-supported anti-SRBC PFC response was increased by the addition of an interleukin 1-containing fraction from the supernatant of the macrophage line P388D1. PFC development in response to TNP-Ficoll had the most stringent requirements and only occurred in the presence of EL-4 sup and B15 sup (IL 2, BCGF-I, BCGF-II, EL-TRF, B15-TRF). These data indicate that different cellular and molecular requirements exist for PFC development in response to types 1, 2, and TD antigens by rat B cells.
Eldridge
J H
JH
Kimura
S
S
Morisaki
I
I
Michalek
S M
SM
Hamaoka
T
T
Hamada
S
S
McGhee
J R
JR
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology*; D000955:Antigens, T-Independent / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D002003:Brucella abortus / Q000276:immunology; D003208:Concanavalin A / Q000494:pharmacology; D005260:Female; D005362:Ficoll / Q000031:analogs & derivatives / Q000276:immunology; D006462:Hemolytic Plaque Technique; D007375:Interleukin-1 / Q000502:physiology; D007376:Interleukin-2 / Q000502:physiology; D015848:Interleukin-5; D007941:Leukemia P388 / Q000276:immunology; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000502:physiology; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D051381:Rats; D011916:Rats, Inbred F344; D013601:T-Lymphocytes / Q000276:immunology*; D014301:Trinitrobenzenes / Q000276:immunology
D000955:Antigens, T-Independent; D007375:Interleukin-1; D007376:Interleukin-2; D015848:Interleukin-5; D008222:Lymphokines; C020529:TNP-ficoll; D014301:Trinitrobenzenes; C021649:concanavalin A-induced helper factors; D003208:Concanavalin A; D005362:Ficoll